



Report from the extraordinary general meeting in Scandinavian Real Heart AB on November 24, 2023

Press release November 24th, 2023

Scandinavian Real Heart AB (the "Company") has on November 24, 2023, held an extraordinary general meeting where mainly the following decisions were made.

Determination of the number of board members.

The meeting resolved to approve the nomination committee's proposal that the number of members of the board of directors shall consist of eight ordinary board members without deputies.

Election of board members.

The meeting resolved to approve the nomination committee's proposal to elect Magnus Öhman, Stuart McConchie and Giovanni Lauricella to the board of directors. The other members remain on the Board of Directors as proposed by the Nomination Committee.

Determination of fees for the Board of Directors

The Meeting resolved, in accordance with the Nomination Committee's proposal, that fees to the Board of Directors shall be paid with SEK 72,500 to each of the new members.

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.